Pierre Fabre Laboratories is now responsible for all global clinical trial activities for the tabelecleucel clinical program Enrollment is ongoing for pivotal, Phase 3 ALLELE Study (NCT03394365) investigating tabelecleucel in patients with EBV+PTLD in Solid Organ Transplant and Allogeneic Hematopoietic Cell Transplant after failure of standard therapy NCT04554914 also open for enrollment to patients with EBV-associated diseases Atara Biotherapeutics resubmitted the tabelecleucel Biologics Licens

Scientists Unveil 4DMedical Imaging Breakthrough that Spo ts Early Lung Disease Missed by Standard Tests LOS ANGELES, July 15, 2025 /PRNewswire/ -- Researchers at Vanderbilt University, Johns Hopkins University, University of Miami, and The Alfred Hospital studied the lungs of subjects including Veterans using technology developed by 4DMedical called X-ray Velocimetry Lung Ventilation Analysis Software (XV LVAS®). Findings of the major, multi-center study were described in the article, "X-ray

FibroScan® is now available in 11 United Digestive clinics, improving early detection and care for liver disease WESTBOROUGH, Mass., July 15, 2025 /PRNewswire/ -- Echosens, the leader in non-invasive liver diagnostics, has partnered with United Digestive, the largest gastroenterology platform in the Southeast, to bring FibroScan® to 11 clinics across Georgia and Florida. This collaboration enhances United Digestive's ability to detect liver disease earlier and develop tailored care plans based o

MINNEAPOLIS, July 15, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a strategic partnership to distribute Spear Bio's next-generation ultrasensitive immunoassays, enabling the detection of low-abundance biomarkers in neurology. Under the agreement, Bio-Techne will distribute Spear Bio's ultrasensitive immunoassays for challenging low-abundance biomarkers, including key Alzheimer's disease biomarkers such as phosphorylated tau 217 (pTau 217), GFAP, neurofilament light

OSLO, Norway, July 15, 2025 /PRNewswire/ -- Reference is made to the stock exchange announcement published by Navamedic ASA ("Navamedic" or the "Company", OSE ticker: "NAVA") on 23 June 2025, regarding Navamedic entering into an asset purchase agreement for the acquisition of the business of dne pharma AS for a total consideration of up to NOK 225 million, whereby NOK 185 million is payable at closing, and the remaining NOK 40 million is payable in two tranches subject to achievement of certain

Pivotal Findings Spotlighted in Plenary Session, Late-Breaking Presentations, and Symposium on Next-Gen Liver Preservation CHICAGO, July 15, 2025 /PRNewswire/ -- Bridge to Life™ Ltd., a global leader in organ preservation and perfusion technology, today announced the presentation of key clinical data at the 2025 World Transplant Congress (WTC), the joint congress of the American Society of Transplantation (AST), the American Society of Transplant Surgeons (ASTS), and The Transplantation Society

REDWOOD CITY, CA, USA I July 14, 2025 I Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for its proprietary, selective cortisol modulator, relacorilant, to treat patients with platinum-resistant o

INGELHEIM, Germany & BALLERUP, Denmark I July 14, 2025 I Boehringer Ingelheim and LEO Pharma today announced an exclusive global license and transfer agreement to commercialize and advance the development of SPEVIGO ® (spesolimab). SPEVIGO ® is an innovative, humanized, and selective monoclonal antibody that targets and blocks the activation of the interleukin-36 (IL-36) receptor – a key signaling pathway in the immune system implicated in the pathogenesis of several autoinflammatory diseases, i

Rahway: Merck, known as MSD in India, is set to begin Phase 3 trials to evaluate the safety and efficacy of 'MK-8527', an investigational once-monthly, oral drug indicated for HIV. In collaboration with the Gates Foundation, the EXPrESSIVE-10 (MK-8527-010) trial will evaluate the safety and efficacy of MK-8527 in women and adolescent girls in 16 countries across sub-Saharan Africa and will begin enrolling in August 2025. The trial is sponsored by Merck and the trial conducting bodies, the Intern

NICE, France--(BUSINESS WIRE)--Caranx Medical (“Caranx”), a French medical device company specializing in the development of an autonomous robot to democratize access to Transcatheter Aortic Valve Implantation (TAVI), a lifesaving procedure, today announced FDA clearance for US commercialization of the world's first AI Software for real-time intra-operative guidance of transcatheter heart valve implantation. The FDA clearance marks a significant milestone of Caranx's strategy towards planned mar